U.S. markets open in 3 hours 1 minute
  • S&P Futures

    4,154.25
    -37.25 (-0.89%)
     
  • Dow Futures

    33,968.00
    -129.00 (-0.38%)
     
  • Nasdaq Futures

    12,643.75
    -203.00 (-1.58%)
     
  • Russell 2000 Futures

    2,003.60
    -4.30 (-0.21%)
     
  • Crude Oil

    75.56
    -0.32 (-0.42%)
     
  • Gold

    1,923.80
    -7.00 (-0.36%)
     
  • Silver

    23.51
    -0.10 (-0.44%)
     
  • EUR/USD

    1.0933
    +0.0021 (+0.20%)
     
  • 10-Yr Bond

    3.3960
    0.0000 (0.00%)
     
  • Vix

    18.56
    +0.69 (+3.86%)
     
  • GBP/USD

    1.2256
    +0.0027 (+0.22%)
     
  • USD/JPY

    128.4670
    -0.1370 (-0.11%)
     
  • BTC-USD

    23,469.26
    -355.20 (-1.49%)
     
  • CMC Crypto 200

    535.90
    -9.41 (-1.73%)
     
  • FTSE 100

    7,828.83
    +8.67 (+0.11%)
     
  • Nikkei 225

    27,509.46
    +107.41 (+0.39%)
     

A number of insiders bought OncoCyte Corporation (NASDAQ:OCX) stock last year, which is great news for shareholders

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase stock, like in OncoCyte Corporation's (NASDAQ:OCX) instance, it's good news for shareholders.

While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.

View our latest analysis for OncoCyte

OncoCyte Insider Transactions Over The Last Year

In the last twelve months, the biggest single purchase by an insider was when CEO, President & Director Ronald Andrews bought US$64k worth of shares at a price of US$1.28 per share. That means that an insider was happy to buy shares at above the current price of US$1.18. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We always take careful note of the price insiders pay when purchasing shares. As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price.

While OncoCyte insiders bought shares during the last year, they didn't sell. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
insider-trading-volume

There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

OncoCyte Insiders Bought Stock Recently

It's good to see that OncoCyte insiders have made notable investments in the company's shares. Not only was there no selling that we can see, but they collectively bought US$182k worth of shares. This is a positive in our book as it implies some confidence.

Does OncoCyte Boast High Insider Ownership?

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. Insiders own 5.1% of OncoCyte shares, worth about US$7.3m, according to our data. Whilst better than nothing, we're not overly impressed by these holdings.

What Might The Insider Transactions At OncoCyte Tell Us?

It's certainly positive to see the recent insider purchases. And the longer term insider transactions also give us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that OncoCyte insiders are expecting a bright future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. To assist with this, we've discovered 4 warning signs that you should run your eye over to get a better picture of OncoCyte.

But note: OncoCyte may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.